Nivolumab without brain radiotherapy is insufficient for the treatment of most patients with brain metastases from clear cell renal cell carcinoma

Affiliations

Editorial

Amit K Chowdhry et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S366.

doi: 10.21037/atm.2019.09.10.

¹ Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: MT Milano: royalties from Wolters Kluwer (UpToDate); the other authors have no conflicts of interest to declare.

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L. Flippot R, et al. J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13. J Clin Oncol. 2019. PMID: 31194611 Clinical Trial.

1. Flippot R, Dalban C, Laguerre B, et al. Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. J Clin Oncol 2019;37:2008-16. 10.1200/JCO.18.02218 - DOI - PubMed
1. Mushti SL, Mulkey F, Sridhara R. Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials. Clin Cancer Res 2018;24:2268-75. 10.1158/1078-0432.CCR-17-1902 - DOI - PubMed
1. George SL, Wang X, Pang H. Cancer Clinical Trials: Current and Controversial Issues in Design and Analysis. CRC Press, 2016.
1. Okada H, Weller M, Huang R, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015;16:e534-42. 10.1016/S1470-2045(15)00088-1 - DOI - PMC - PubMed
1. Brastianos PK, Carter SL, Santagata S, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov 2015;5:1164-77. 10.1158/2159-8290.CD-15-0369 - DOI - PMC - PubMed